

No	Reference Number	IRAS No	Title	Target number of participants agreed?	Target range minimum	Target range maximum	Target date to recruit participants agreed?	Date agreed to recruit number of participants	Total no of patients recruited at the agreed target date	Date Trial Closed to Recruitment	Total Number of Study Participants Recruited	Reason for closure of trial
1	15/WM/0056	159740	Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit	Range Agreed	35	60	Date Agreed	24/02/2018	54	24/02/2018	54	Recruitment Finished
2	14/YH/1141	161305	A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy	Number Agreed	2	2	Date Agreed	15/03/2018	2	30/11/2017	2	Withdrawn By Sponsor
3	15/NW/0868	188121	A Phase 3 study of Efficacy, Safety and Tolerability of Chronocort® compared with Standard Glucocorticoid Replacement Therapy in the treatment of Congenital Adrenal Hyperplasia.	Number Agreed	7	7	Date Agreed	31/01/2018	10	31/01/2018	10	Recruitment Finished
4	14/SC/1161	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster des system in unselected patients representing everyday clinical practice.	Number Agreed	50	50	Date Agreed	31/05/2018	221	03/05/2018	221	Recruitment Finished.
5	15/LO/0545	172357	Clinical and device functional Assessment of Real world ICD pAtients - CARAT	Number Agreed	10	10	Date Agreed	31/10/2017	10	31/10/2017	10	Recruitment Finished
6	16/YH/0454	211679	A prospective multi-centre observational study to evaluate the capabilities of a portable magnetocardiograph (MCG) device to rule-out acute coronary syndrome (ACS) in patients who present to the emergency department with chest pain symptoms consistent with ACS.	Number Agreed	175	175	Date Agreed	30/04/2018	175	30/04/2018	175	Recruitment Finished
7	16/EM/0278	208188	A Phase III extension study of efficacy, safety and tolerability of Chronocort® in the treatment of congenital adrenal hyperplasia.	Range Agreed	1	7	Date Agreed	12/03/2018	10	12/03/2018	10	Recruitment Finished

8	16/LO/1697	212844	A Phase III randomised, controlled clinical trial of Pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy in subjects with advanced or metastatic urothelial carcinoma.	Number Agreed	3	3	Date Agreed	30/04/2018	4	31/05/2018	4	Recruitment Finished
9	16/WM/0359	211812	A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects with Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma.	Range Agreed	2	5	Date Agreed	30/05/2020	4	16/01/2018	4	Recruitment Finished
10	16/YH/0450	213782	20150288: A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)	Range Agreed	2	5	Date Agreed	30/06/2018	3	04/05/2018	3	Recruitment Finished
11	16/SC/0391	208610	A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis.	Range Agreed	4	21	Date Agreed	01/05/2019	19	16/04/2018	19	Recruitment Finished
12	16/EE/0463	214371	COMPLEEMENT-1: An open-label, multicentre, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease	Number Agreed	4	4	Date Agreed	27/10/2017	4	16/10/2017	4	Recruitment Finished
13	17/YH/0388	235066	A multi-center, double-blind, randomized, placebo-controlled study to assess the pharmacodynamics, pharmacokinetics, tolerability, and safety of a single subcutaneous injection of ACT-246475 in adults with stable coronary artery disease	Number Agreed	13	13	Date Agreed	31/08/2018	66	31/08/2018	66	Recruitment Finished

14	18/NW/0008	231939	A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Countries for Dengue	Number Agreed	5	5	Date Agreed	31/08/2018	10	14/09/2018	10	Recruitment Finished
15	16/YH/0024	196244	A Phase 1 Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis.	Number Agreed	6	6	Date Agreed	30/06/2019	7	30/06/2018	7	Recruitment Finished
16	12/YH/0498	102641	An Open, Phase I, Exploratory Study of MTL-005 Radiosensitization in Patients With Advanced Carcinoma of the Head and Neck: Part 1 to Evaluate Safety in a Dose Escalation Design in Patients Indicated for Palliative Radiotherapy, Part 2 to Evaluate Safety and Efficacy in a Dose-Escalation Design in Patients Indicated for Cisplatin Chemoradiotherapy - MOREX	Number Agreed	7	7	Date Agreed	20/03/2018	4	20/03/2018	4	Recruitment Finished
17	15/YH/0117	173811	A prospective, multicenter, single-arm, open-label, Phase 4 study to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary Arterlal hypeRtension assessed by cardiac magnetic resonance imaging - REPAIR	Range Agreed	1	2	Date Agreed	30/06/2018	0	19/07/2018	0	Recruitment Finished

18	15/LO/1289	181953	An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures - CARD 3867 VOYAGER PAD	Range Agreed	20	40	Date Agreed	31/01/2018	6	08/12/2017	6	Recruitment Finished
19	16/LO/0351	190075	A double blind, randomized placebo controlled crossover multiple dose study of LJN452 to assess safety, tolerability and efficacy in patients with primary bile acid diarrhea (pBAD)	Number Agreed	5	5	Date Agreed	16/11/2017	3	16/11/2017	3	Recruitment Finished
20	15/EM/0179	177000	Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low Ejection Fraction UNTOUCHED	Range Agreed	7	50	Date Agreed	31/12/2019	6	27/02/2018	6	Recruitment Finished
21	16/EE/0040	196164	A Phase II, blinded, randomized, multicenter, Multiple Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients with Non Healing Neuropathic Diabetic Foot Ulcers.	Number Agreed	1	1	Date Agreed	24/02/2018	0	08/01/2018	0	Recruitment Finished
22	16/LO/1138	207606	A Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD).	Number Agreed	1	1	Date Agreed	30/11/2018	0	17/01/2018	0	Withdrawn By Sponsor
23	16/EM/0376	211430	A 12-week, randomized, multicenter, double-blind, placebo-controlled, 3-arm, parallel-group, phase 3 trial to evaluate the efficacy and safety of 2 doses of AQX-1125 targeting the SHIP1 pathway in subjects with interstitial cystitis/bladder pain syndrome followed by a 2-arm, 14 or 40 week open label extension	Number Agreed	4	4	Date Agreed	31/03/2018	1	15/02/2018	1	Recruitment Finished

24	16/NW/0606	211110	A Phase II single-arm, open-label monotherapy clinical trial of Pembrolizumab (MK-3475) in locally advanced/metastatic renal cell carcinoma (mRCC) (KEYNOTE-427)	Number Agreed	4	4	Date Agreed	20/03/2020	0	24/04/2018	0	Withdrawn By Sponsor
25	16/EM/0384	182787	CV 185316: An Open-label, 2x2 Fractorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention	Number Agreed	8	8	Date Agreed	31/05/2018	4	10/04/2018	4	Recruitment Finished
26	17/NE/0115	218417	Multi-center, international, double-blind, two-arm, randomized, placebo-controlled phase II trial of pirfenidone in patients with unclassifiable progressive fibrosing ILD	Range Agreed	3	4	Date Agreed	23/04/2018	1	26/04/2018	1	Withdrawn By Host
27	17/NW/0180	220257	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy	Range Agreed	1	2	Date Agreed	30/09/2018	0	08/08/2018	0	Recruitment Finished
28	16/SC/0653	215441	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	Number Agreed	4	4	Date Agreed	31/08/2018	0	27/04/2018	0	Withdrawn By Sponsor
29	16/YH/0506	212039	A Randomized, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD	Number Agreed	2	2	Date Agreed	22/12/2017	1	30/11/2017	1	Recruitment Finished

30	17/LO/0380	218003	A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of Crenezumab in patients with prodromal to mild Alzheimer's disease - Cread 2	Number Agreed	6	6	Date Agreed	30/03/2018	0	05/04/2018	0	Withdrawn by Sponsor
31	16/EM/0443	208418	STEM – A multicentre Phase 2 study of SFX-01 treatment and evaluation in patients with Estrogen Receptor (ER) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative metastatic breast cancer progressing on either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant	Range Agreed	4	10	Date Agreed	24/07/2018	0	24/07/2018	0	Recruitment Finished
32	17/LO/1147	222154	A Randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy	Number Agreed	6	6	Date Agreed	31/05/2018	4	23/03/2018	4	Recruitment Finished
33	16/EM/0436	213166	Single arm study of ALXN1210 in complement inhibitor treatment-naïve adult and adolescent patients with Atypical Hemolytic Uremic Syndrome (aHUS)	Number Agreed	1	1	Date Agreed	31/12/2018	0	25/05/2018	0	Recruitment Finished
34	17/LO/0169	214075	Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study	Number Agreed	4	4	Date Agreed	31/05/2018	0	27/04/2018	0	Recruitment Finished
35	17/NE/0377	233847	A phase 3b, multicentre, prospective, randomized, double blind, placebo-controlled study to reduce incidence of pre-dialysis hyperkalemia with Sodium Zirconium Cyclosilicate (DIALIZE)	Number Agreed	3	3	Date Agreed	13/09/2018	0	14/08/2018	0	Recruitment Finished

36	17/YH/0390	233236	EFC14867 – A 26-week Randomised, Double-blind, Controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Empagliflozin, and Placebo in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin	Number Agreed	5	5	Date Available	30/11/2018	0	14/09/2018	0	Recruitment Finished
----	------------	--------	--	---------------	---	---	----------------	------------	---	------------	---	----------------------